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RAD51 is a recombinase involved in the homologous recombination of
double-strand breaks in DNA. RAD51 forms oligomers by binding to another
molecule of RAD51 via an ‘FxxA’ motif, and the same recognition sequence
is similarly utilised to bind BRCA2. We have tabulated the effects of muta-
tion of this sequence, across a variety of experimental methods and from rele-
vant mutations observed in the clinic. We use mutants of a tetrapeptide
sequence to probe the binding interaction, using both isothermal titration
calorimetry and X-ray crystallography. Where possible, comparison between
our tetrapeptide mutational study and the previously reported mutations is
made, discrepancies are discussed and the importance of secondary structure
in interpreting alanine scanning and mutational data of this nature is
considered.
Keywords: alanine scanning; biophysics/ITC; peptides; protein–protein
interaction; RAD51; X-ray crystallography
Eukaryotic RAD51, archeal RadA and prokaryotic
RecA are a family of ATP-dependent recombinases
involved in homologous recombination (HR) of
double-strand breaks in DNA [1]. RAD51 interacts
with BRCA2, and is thought to localise RAD51 to
sites of DNA damage [2,3]. Both BRCA2 and RAD51
together are vital for helping to repair and maintain a
high fidelity in DNA replication. BRCA2 especially
has garnered much attention in a clinical context, as
many mutations have been identified that drive an
increased risk of cancer in individuals [4,5]. Although
the inactivation of the BRCA2:RAD51 DNA repair
pathway can cause genomic instability and eventual
tumour development, an inability to repair breaks in
DNA may also engender a sensitivity to ionising
radiation [6,7]. For this reason it is hypothesised that
in tumour cells with an intact BRCA2:RAD51 repair
pathway, small molecules which prevent the interac-
tion between RAD51 and BRCA2 may confer
radiosensitivity by disabling the HR pathway [8]. The
interaction between the two proteins is mediated by
eight BRC repeats, which are characterised by a con-
served ‘FxxA’ motif [9]. RAD51 and RadA proteins
also contain an ‘FxxA’ sequence (FTTA for human
RAD51) through which it can bind to other RAD51
and RadA molecules, and oligomerise to form higher
order filament structures on DNA. The common FxxA
motifs of both the BRC repeats and RAD51
oligomerisation sequence are recognised by the same
FxxA-binding site of RAD51.
In general, the dominant contribution of certain
residues to the overall binding energy of a protein–
protein interaction are known as ‘hot-spot’ residues.
Interestingly, small molecule inhibitors of PPIs are
Abbreviations
BRCA2, breast cancer type-2 susceptibility protein; HR, homologous recombination; ITC, isothermal titration calorimetry; PPI, protein–protein
interaction; SAR, structure activity relationship.
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often found to occupy the same pockets which are
otherwise occupied by hot-spot residues in the native
complex. It is therefore of great interest to identify
hot-spots in an effort to guide drug discovery efforts
against a PPI. Further, a correlation between residues
that are strongly conserved and hot-spot residues has
been reported [10]. Purely based on the amino acid
consensus sequence reported by Pellegrini et al., [11]
phenylalanine and alanine would both be expected to
be hot-spots and to a lesser extent, threonine. How-
ever, whilst the identification of highly conserved
residues may be a good starting point for identifying
hot-spots, experimental validation by mutation of
these sequences is vital.
The importance of residues in the FxxA motif has
been probed by a variety of techniques, collated in
Table 1. Briefly, mutating phenylalanine to glutamic
acid inactivated the BRC4 peptide and prevented
RAD51 oligomerisation [11,12]. A phenylalanine-trun-
cated BRC4 is also found to be inactive [13], however,
introducing a tryptophan for phenylalanine was found
to have no significant effect on BRC4 affinity [12]. A
glutamine replacing the histidine in BRC4 maintains
BRC4 activity [13]. The ability of BRC3 to interact
with RAD51 nucleoprotein filaments is disrupted when
threonine is mutated to an alanine [3]. Similarly,
mutating alanine to glutamic acid in the RAD51
oligomerisation sequence [11] or to serine in BRC4
[13] leads to loss of interaction in both cases. The
BRC5 repeat in humans has serine in the place of ala-
nine, and is thought to be a nonbinding repeat [12].
Mutations identified in the clinic, in the FxxA region
of the BRC repeats of BRCA2 are collated in Table 1
[14]. It is difficult to state the clinical relevance of these
mutations as they are annotated as ‘unvalidated’, that
is, it is not known whether they contribute to the dis-
ease phenotype or are neutral variants. For complete-
ness, we present them here with this caveat, and to
make the comment that these clinical mutations are
consistent with abrogating the interaction with
RAD51.
In this work, we report the most detailed study of
systematic mutations of peptides to probe the FxxA-
binding motif to date. We have chosen to focus on
tetrapeptides, which allows us to examine the effect of
mutation on the fundamental unit of binding, FxxA,
rather than in the context of either the BRC repeat or
self-oligomerisation sequence. Affinities of peptides
were measured directly using Isothermal Titration
Calorimetry (ITC) and the structures of many of the
peptides bound to humanised RadA were determined
by X-ray crystallography. The use of ITC is generally
perceived as a gold-standard in protein–ligand charac-
terisation, rather than a competitive assay which may
be prone to aggregation artefacts. Wild-type human
RAD51, however, is a heterogeneous mixture of oligo-
mers and when monomerised by mutation, is highly
unstable. In this context, we have previously reported
the use of stable monomeric forms of RAD51, human-
ised from Pyrococcus furiosus homologue RadA, for
ITC experiments and X-ray crystallography [8,15].
Materials and methods
Peptide synthesis
Peptides were synthesised using solid-phase FMOC chem-
istry by Alta Biosciences (Birmingham, UK) or the Protein
Table 1. Summary of FxxA-relevant mutations previously reported and degree of characterisation. The mutation, relevant peptide context,
resulting FxxA motif sequence and experimental technique for each entry is given. For clarity, mutated residues are shown in bold.
Mutation contexta Mutation FxxA motif Technique used Effect
RAD51 (FTTA) F86E ETTA Immunoprecipitation [11] No binding
BRC4 (FHTA) F1524E EHTA Competitive ELISA [12] Peptide inactive
BRC4 (FHTA) F1524W WHTA Competitive ELISA [12] Comparable activity to WT
BRC4 (FHTA) F1524V VHTA BRCA2 mutations database [14] –
BRC4 (FHTA) DF1524 -HTA Dissociation of RAD51-DNA complex [13] Peptide inactive
BRC4 (FHTA) H1525Q FQTA Dissociation of RAD51-DNA complex [13] Comparable activity
BRC7 (FSTA) S1979R FRTA BRCA2 mutations database [14] –
BRC3 (FQTA) T1430A FQAA RAD51:DNA bandshift assay [3] Peptide inactive
BRC3 (FQTA) T1430A FQAA Electron microscopic visualisation of
nucleoprotein filaments [3]
Peptide inactive
BRC1 (FRTA) T1011R FRRA BRCA2 mutations database [14] –
BRC2 (FYSA) S1221P FYPA BRCA2 mutations database [14] –
BRC2 (FYSA) S1221Y FYYA BRCA2 mutations database [14] –
RAD51 (FTTA) A89E FTTE Immunoprecipitation [11] No binding
BRC4 (FHTA) A1527S FHTS Dissociation of RAD51-DNA complex [13] Peptide inactive
a The wild-type FxxA sequence is indicated in parenthesis.
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and Nucleic Acid Service at the Department of Biochem-
istry (University of Cambridge). All peptides prepared and
used in the study were N-acetylated and C-amide termi-
nated.
Protein preparation
Protein expression and purification was performed as
described previously [15]. In brief, monomeric HumRadA2
was expressed in E. coli using T7-based expression vector
at 37 °C for 3 h. Soluble cell lysate was heat treated to pre-
cipitate most of the cellular proteins and the soluble frac-
tion containing HumRadA2 was purified using a
combination of cation exchange chromatography at pH 6.0
and size-exclusion chromatography in 10 mM MES,
100 mM NaCl pH 6.0 buffer. Protein concentration was
determined using the calculated extinction coefficient at
280 nm, and stored at 80 C in small aliquots after flash
freezing.
Isothermal titration calorimetry
Isothermal titration calorimetry experiments were per-
formed at 25 °C on a MicroCal iTC200. HumRadA2
(600 lM in 20 mM MES pH 6.0 with 100 mM NaCl and
0.5 mM EDTA) was diluted with Tris buffer (200 mM, pH
7.5 with 100 mM NaCl) to 64–83 lM. Peptides were dis-
solved in MilliQ water (50 mM) and an aliquot taken and
diluted with 200 mM Tris, pH 7.5, 100 mM NaCl to give a
ligand solution of 2.5–5 mM. The peptide solution was
titrated into the protein solution; 16 injections (2.4 lL) of
4.8 s duration were made at 80-s intervals. The initial injec-
tion of ligand (0.4 lL) was discarded during data analysis.
Control experiments of peptides to buffer showed insignifi-
cant heats. The data were processed and thermodynamic
parameters obtained by fitting the data to a single-site-
binding model using Origin software and fixing the stoi-
chiometry as 1.0 for weak-binding ligands [16]. All data
from ITC measurements are shown in the Figs S1 and S2.
X-ray crystallography
Monomerised RadA proteins were crystallised in the same
conditions as described previously [15]. Peptides were
soaked into the crystals at 2–5 mM concentration overnight
in the presence of 10% glycerol as a cryoprotectant. Crys-
tals were cryo-cooled in liquid nitrogen and data collected
at synchrotron light sources and processed using XDS:
details of this are found in crystallographic table (Table S1
in Supporting Information). Structures were solved by
molecular replacement using unliganded, monomeric RadA
coordinates (PDB: 4b3b, after removal of FHTA peptide)
as a search model and refined with an automated procedure
using Refmac5 [17]. After inspection of the resulting elec-
tron density, the bound peptides were modelled into the
density and structures were further refined using Refmac5
[18] and phenix.refine [19], and manually rebuilt using Coot
[20]. Coordinates and structure factors have been deposited
in the PDB under accession codes as listed in Table 2 and
in the crystallographic data table in the Supporting
Table 2. Summary of peptide-binding data determined by ITC against HumRadA2. Mutated residues are highlighted in bold. All peptides
were N-acetylated and C-amide terminated.
Table entry Peptide KD/lM DH/calmol1 TDS/calmol1 PDB code
First position variation
1 FHTA 280  20 2388  94 2453 4b3b [15]
2 WHTA 93  3 2768  34 2727 5fow
Second position variation
3 FATA 280  29 1820  109 3010 5fpk*
4 FNTA 613  44 4036  177 346 –
5 FPTA No detectable binding –
Third position variation
6 FHPA 113  3 2155  26 3218 5fou
7 FHAA 675  60 7948  466 3636 5fox
Fourth position variation
8 FHTG 1590  300 5518  924 1702 5fov
9 FHTU 680  51 14 600  771 10 281 5fot
Combination
10 WHPA 330  25 6801  318 2044 –
Peptide truncations
11 FH No binding detected
No binding detected
No binding detected
–
12 FHT –
13 HTA –
* Structure solved with wild-type RadA.
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Information. With the exception of FATA peptide com-
plex, which was crystallised with wild-type RadA, the struc-
tures are determined using HumRadA1 mutant.
Sequence analysis
Sequences of mammalian RAD51 proteins and archeal
RadA orthologues were obtained from Ensembl (www.ense
mbl.org) and Uniprot (www.uniprot.org) databases.
Sequences were aligned using ClustalX2, and aligned
sequences for the FxxA motifs were used in WebLogo (we-
blogo.berkely.edu/logo.cgi) server [21] to derive the consen-
sus diagrams shown in Figs 1 and 4. All the sequences used
in these analyses are shown in Figs S4, S5 and S6.
Results
We have mutated and truncated the tetrapeptide epi-
tope FHTA, and examined the effects both structurally
and on the binding affinity with humanised RadA. As
a comparative reference, we are using the FHTA
sequence derived from the most tightly binding BRC
repeat, BRC4 [22]. The peptides used are N-acetylated
and C-amide terminated in order to provide the most
relevant peptide in the context of a longer peptide
chain. A summary of the peptide sequence, PDB codes
and KD data measured by ITC with the corresponding
DH and TDS values are collated in Table 2.
Phe1524 of BRC4 binds in a small surface pocket of
human RAD51, defined by the hydrophobic side
chains of residues Met158, Ile160, Ala192, Leu203 and
Met210. The residue is highly conserved across BRC
repeats and oligomerisation sequences. Consistent with
this, the truncated HTA tripeptide could not be
detected to bind to humanised, monomeric RadA,
HumRadA2 (Table 2, entry 13). As previously dis-
cussed, there is some evidence that substituting a tryp-
tophan for the phenylalanine at this position was
tolerated in the context of BRC4 [12]. Therefore, the
WHTA peptide was tested and found to not only be
tolerated, but to increase the binding affinity of the
peptide approximately threefold.
The second position of the tetrapeptide was found
to be largely invariant to changes in the side chains
that were investigated. The residue makes no interac-
tions with the RAD51 protein, but may make an inter-
nal hydrogen bond with Thr1520 in the context of
BRC4, Fig. 3A. Replacing the histidine with an aspar-
agine, chosen to potentially mimic the hydrogen bond
donor–acceptor nature of histidine, resulted in a mod-
erate, twofold decrease in potency (Table 2, entry 4).
Mutating to an alanine, recapitulated the potency of
FHTA, implying that the interactions made by his-
tidine do not contribute overall to binding affinity
(Table 2, entry 3). FPTA was also tested, but was
Fig. 1. Conservation of FxxA motif (A)
BRC4 peptide (green cartoon) bound to
truncated human RAD51 (grey surface)
(PDB: 1n0w, [11]). The blue dashed box
highlights the FxxA interaction pocket. (B)
Two interacting protein molecules of
RAD51 from Saccharomyces cerevisiae
are shown. One RAD51 (green cartoon)
interacts with another molecule of RAD51
(grey and pink surface) via the FxxA
pocket indicated by the dashed blue box.
The N-terminal domain of one RAD51
protomer is highlighted in pink for clarity
and the green arrow indicates the location
of this protomer’s FxxA oligomerisation
sequence (PDB: 1szp, [29]). (C)
Conservation of FxxA motif across the
human BRC repeats and (D) across 21
eukaryotic RAD51s and 24 RadAs, with
the size of the letters proportional to the
degree of conservation. Sequence figures
generated using Weblogo 3.0 [21],
sequence details are found in the
Supporting Information.
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found to have no affinity for the protein (Table 2,
entry 5). Modelling suggests that a proline in the sec-
ond position would be expected to clash sterically with
the surface of the protein, and provides a rationale for
the lack of binding observed.
Threonine was mutated to an alanine, resulting in
only a moderately weaker KD (twofold, Table 2, entry
7). In the context of a tetrapeptide at least, this result
implies a lack of importance of a threonine at this
position. Interestingly, it was found that a proline at
this position improved the affinity almost threefold, to
113 lM (Table 2, entry 6). This beneficial mutation
was incorporated with another previously identified
variant to produce the peptide WHPA. Disappoint-
ingly, the combined effect of the mutations was not
additive and the potency was weakened to 690 lM.
While the importance of the phenylalanine may be
possible to predict from examination of the crystal
structure, the alanine appears to be of much less
importance in this regard. It is, however, a highly con-
served residue and clearly of interest for systematic
mutation. Removing the alanine residue entirely pro-
duced the truncated tripeptide FHT, which did not
bind (Table 2, entry 12). The unnatural amino acid, a-
amino butyric acid (U), was introduced at the fourth
position, positioning an ethyl group into the alanine
pocket (Table 2, entry 9). Perhaps surprisingly, it was
accommodated and the affinity dropped only by two-
fold as compared to FHTA. The effect of simply
removing the b-carbon of alanine, by mutation to gly-
cine (FHTG), produced an approximately sixfold drop
in binding affinity (Table 2, entry 8). This is in line
with the observation that alanine is not 100% con-
served and some archeal RadA proteins contain a
glycine in the place of alanine [23].
Structural characterisation of peptide complexes
Structures of the key tetrapeptides were solved by
soaking into crystals of a humanised form of RAD51,
HumRadA1, which we have previously reported as a
convenient surrogate system for RAD51 crystallogra-
phy [15]. The corresponding PDB codes are indicated
in Table 2 and crystallographic data are found in the
Supporting Information. All structures are of high res-
olution (1.2–1.7 A) and the electron density for the
peptide was clearly visible after the first refinement
using unliganded RadA coordinates (Fig. S1).
Some of the SAR observed in the binding analysis
can be interpreted in terms of these X-ray crystal
structures. For example, an overlay of the bound poses
of the ligands FHTA and FHPA (Fig. 2B) reveals a
high similarity in the binding modes, indicating that
the conformational rigidity conferred by the proline is
compatible with the FHTA-binding mode, and a
reduction in an entropic penalty of binding may be the
source of the improvement in affinity. WHTA peptide
shows a relative dislocation when compared to FHTA
(Fig 2A), with the entire ligand backbone of WHTA
shifted to accommodate the change in the position of
the main chain carbon of the first residue, as the larger
indole side chain fills the Phe pocket. This shift is
translated all the way to the alanine side chain. It is
possible that this mutation is beneficial in the tetrapep-
tide context and neutral in the full-length BRC4 con-
text because the smaller peptide is less constrained and
allowed to explore more conformations. An attempt to
combine both the tryptophan and proline mutations,
however, led to no improvement for WHPA peptide
compared to FHTA. One possible explanation is that
Fig. 2. Comparison of different peptide complexes (A) Overlay
with FHTA (grey) and WHTA (purple) showing a small relative
displacement of the peptide backbone. (B) Superposition of FHTA
(grey) and FHPA (yellow), showing conservation of backbone
orientation (C) Overlay of FHTU (green), FHTA (grey) and FHTG
(cyan).
1098 FEBS Letters 590 (2016) 1094–1102 ª 2016 The Authors. FEBS Letters published by John Wiley & Sons Ltd on behalf of Federation of European
Biochemical Societies.
SAR of FxxA motif in BRCA2 D. E. Scott et al.
the ‘shifted’ binding mode observed in WHTA was not
compatible with the conformational restriction that the
proline of WHPA introduced.
The thermodynamic data of peptide binding are also
shown in Table 2. Although we have both thermody-
namic data and high-quality X-ray structural informa-
tion for some of the mutant peptides, we do not
attempt to interpret differences in thermodynamic pro-
files between ligands, that is, to analyse DDH and
DDS. Although DH and DS are tabulated, the KDs
measured are relatively weak and necessarily per-
formed under low c-value conditions. In this experi-
mental regime, nonsigmoidal curves are generated and
therefore errors in DH are expected to be much higher
than the errors from model fitting given in Table 2
[16]. As DS is derived from DG by subtracting DH,
errors in DH will be correlated with errors in DS, giv-
ing rise to a ‘phantom’ enthalpy–entropy compensa-
tion. Such effects have been discussed by Klebe [24]
and Chodera and Mobley [25] and will frustrate
attempts to interpret the measured DDH and DDS.
Understanding mutations, residue conservation
and epitope secondary structure
The conserved phenylalanine and alanine residues of
the FHTA sequence were both found to be essential
for binding by ITC. Conversely the second position
histidine residue, corresponding to the unconserved
His1525 in the BRC4 sequence, could be mutated
without significant effect on the peptide affinity. The
more general correlation between hot-spot residues in
protein–protein interactions and the high conservation
of such residues has been previously reported [10,26].
Interestingly, however, the highly conserved threonine
residue could be mutated without affecting the peptide
affinity. This unexpected result, in the light of its very
high conservation in the BRC and oligomerisation
sequences, begs the question of what the role of
Thr1526 is and highlights a potential pitfall and need
for caution in the experimental design of alanine muta-
tion studies.
As the FHTA peptide is potentially a surrogate pep-
tide for both the BRC repeat peptides and the RAD51
self-oligomerisation peptide, it is useful to examine the
role of Thr1526 (BRC4) and the analogous Thr87
(RAD51) in both binding contexts in more detail.
Structural information for these two interactions is
limited. Only one structure of BRC4 is published in
complex with human RAD51 (PDB: 1n0w). Figure 3A
shows the binding pose of BRC4 when bound to
RAD51 and the intrapeptide hydrogen bonds that are
made by BRC4. While Phe1524 and Ala1527 are bur-
ied in hydrophobic pockets on the surface, His1525 is
close enough to form a hydrogen bond with the car-
bonyl of Thr1520, but the rotamer of His1525, sup-
ported by clearly positioned water molecules, is not
compatible with hydrogen bonding. Also, Thr1520 is
constrained by crystal contacts in this structure. Lack
of conservation of this residue supports the idea that
this interaction is not crucial for RAD51:BRC repeat
binding.
Fig. 3. (A) Highlight of intra-BRC4 interactions when bound to RAD51 (omitted for clarity) (PDB: 1n0w), with key residues shown in colour.
(B) Intrapeptide interactions from oligomerisation epitope of S. cerevisiae RAD51 when bound to next RAD51 in the filament (PDB: 1szp).
Colouring as in (A). Residue numbering relates to the S. cerevisiae RAD51 protein, the corresponding human residues are in parentheses.
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Either a threonine or serine is most commonly
found in the third position of the FxxA motif.
Thr1526 makes no direct interactions with the RAD51
protein, but instead forms a hydrogen bond network
with the highly conserved S1528 and K1530 (Fig. 1C).
The high degree of conservation of these three residues
suggests an important possible role in facilitating a
turn and stabilising the conformation of the peptide as
it continues its way to a second interaction site on the
side of RAD51. With respect to understanding the
RAD51:RAD51 interaction, no human crystal struc-
ture has been published, however, several oligomeric
structures of archaeal RadA as well that of Saccha-
romyces cerevisiae RAD51 have been reported [27–29].
Figure 3B shows a highlight of the FxxA portion of
oligomerisation peptide from the S. cerevisiae RAD51
structure, with residues in parentheses corresponding
to the human RAD51 protein. The conserved thre-
onine residue at the third position forms a hydrogen
bond with the peptide backbone amide, which forms
the base of an a-helix.
In both structural contexts, the role of the third posi-
tion threonine in FxxA seems to be in stabilising sec-
ondary structure; a b-turn in the case of BRC binding
and an a-helix in the case of RAD51 oligomerisation. In
the tetrapeptide context these secondary interactions are
not present and mutation of threonine to alanine would
be expected to have little effect on affinity. In line with
this, although we observe a slight twofold weakening of
peptide affinity, the effect is far from being as drastic or
inactivating as reported in longer peptide backgrounds
[3]. It would be interesting to investigate the importance
of this residue in the context of the BRC4 peptide, and
the oligomerisation peptide. Rather than indifference to
alanine mutation, a significant effect, via lack of sec-
ondary structure stabilisation, would be predicted, as
indeed has been reported for BRC3 [3].
Conclusions
The key observations from this work are shown in
Fig 4. Two residues in the FxxA motif, phenylalanine
and alanine, are highly conserved (Fig 4a). Phenylala-
nine mutated to tryptophan, in the context of the
tetrapeptide improved potency, contrary to the
reported result of comparable activity in the context of
BRC4 [12]. Proline at the third position similarly
improved potency. Activity was lost by mutating the
terminal alanine to glycine, but recovered somewhat
with the novel a-amino butyric acid (U). Threonine
was found to be relatively unimportant in the tetrapep-
tides but has been previously reported to be crucial in
the context of BRC3. The reason for this disconnec-
tion is suggested to be that threonine plays a role in
stabilising the b-turn in the BRC repeats, which is
absent in the tetrapeptides studied. This may lead to a
more general caution, that hot-spot data should be
interpreted by considering the bound interaction with
the protein, as well as the potential role in stabilising
the bound peptide secondary structure. In either case,
the requirement for structural data in correctly inter-
preting alanine-scanning experiments is reinforced.
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